|
Bruno Strigini is group vice presidentand president, EUCAN region II, for the Global Pharmaceutical Business of Schering-Plough Corporation's Europe-based regional organization (EUCAN). This region encompasses Austria, Belgium, Greece, the Netherlands, Portugal, Switzerland, Central & Eastern Europe, the Middle East and Africa.
With an extensive background in the international pharmaceutical industry, Strigini came to Schering-Plough from UCB-Celltech, Brussels, Belgium, where he served as president for international operations. Before that position, Strigini was in charge of UCB Japan/Asia-Pacific and was head of global marketing, business development and strategy. Strigini's earlier career included positions at SmithKline Beecham in the U.K. and New Zealand and the Fournier Group in France, the UK, and Spain.
Strigini holds a master's degree in microbiology from Heriot-Watt University in Edinburgh, Scotland, a doctorate of pharmacy from the University of Montpellier, France, and an M.B.A. from IMD, Lausanne, Switzerland.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
| 